Simultaneous estimation of Losartan and Atenolol by UV Spectrophotometric Method

Losar-beta is available for the treatment of hypertension. It contains losartan potassium (LS; 50mg) and atenolol (AT; 50mg). In the present study, simple, rapid, precise and accurate method for the simultaneous estimation of these drugs have been developed and validated by UV spectrophotometry. The method was validated with respect to its linearity, limit of quantitation (LOQ), limit of detection (LOD), precision and accuracy. In this method the LS and AT were scanned with water: methanol (80:20) as solvent and λmax were found to be at 232 and 275 nm for LS and AT respectively. For LS (A1 = 0.0054 Cx + 0.0634 Cy) and AT (A2 = 0.0028Cx + 0.0128Cy). The equations were developed by Vierodt’s method. The LOD was found to be 0.380 μg/mL for LS and 0.860 μg/mL for AT. LOQ was 1.160 μg/mL for LS and 2.600 μg/mL for AT. The %RSD for day to day precision was found to be 0.0060 for LS and 0.0200 for AT. Percentage recovery was found to be 99.32 ± 0.08 for LS and 99.54± 0.12 for AT. The linearity was found to be in the concentration range of 5-50 μg/mL for LS and AT. Statistical analysis proves that, the method is repeatable and selective for the analysis of LS and AT. The result of recovery studies for tablet was found to be nearly 100% showing no interference due to excipients. This method for simultaneous estimation of LS and AT is quite accurate, precise, economic, simple and rapid, hence can be employed for routine analysis in quality control laboratories. Keyword – losartan, atenolol, UV spectrophotometry, method validation, simultaneous estimation.